Do analysts rate HCM or HIK?

Hikma Pharmaceuticals has a consensus price target of GBX 2,085.83, suggesting a potential upside of 36.24%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Hikma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media prefer HCM or HIK?

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 3 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.05 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hikma Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, INDV or HCM?

Indivior has higher revenue and earnings than HUTCHMED. Indivior is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior £1.40B 1.38 -£2.36M -£1.21 N/A HUTCHMED £549.12M 3.04 -£52.98M £2.00 96.00

Is INDV or HCM more profitable?

HUTCHMED has a net margin of 163.84% compared to Indivior's net margin of 11.44%. HUTCHMED's return on equity of 36.88% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 11.44% -23.90% 2.37% HUTCHMED 163.84% 36.88% -5.90%

Which has higher valuation and earnings, HCM or ERGO?

Ergomed has lower revenue, but higher earnings than HUTCHMED. Ergomed is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED £549.12M 3.04 -£52.98M £2.00 96.00 Ergomed £152.09M 0.00 £15M £0.29 N/A

Is HCM or ERGO more profitable?

HUTCHMED has a net margin of 163.84% compared to Ergomed's net margin of 9.87%. HUTCHMED's return on equity of 36.88% beat Ergomed's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED 163.84% 36.88% -5.90% Ergomed 9.87% 18.08% 10.16%

HUTCHMED (HCM) Competitors

GBX 192 -8.00 (-4.00%)

As of 09/11/2026 12:29 PM Eastern

Compare

HCM vs. DPH, HIK, INDV, VEC, and ERGO

Should you buy HUTCHMED stock or one of its competitors? HUTCHMED's main competitors and comparable companies include Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), Indivior (INDV), Vectura Group (VEC), and Ergomed (ERGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HUTCHMED compare to Dechra Pharmaceuticals?

HUTCHMED (LON:HCM) and Dechra Pharmaceuticals (LON:DPH) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

20.7% of HUTCHMED shares are held by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are held by institutional investors. 2.8% of HUTCHMED shares are held by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, HUTCHMED had 3 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 3 mentions for HUTCHMED and 0 mentions for Dechra Pharmaceuticals. HUTCHMED's average media sentiment score of 0.00 equaled Dechra Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
HUTCHMED	Neutral
Dechra Pharmaceuticals	Neutral

HUTCHMED has a net margin of 163.84% compared to Dechra Pharmaceuticals' net margin of -3.66%. HUTCHMED's return on equity of 36.88% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	163.84%	36.88%	-5.90%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

Dechra Pharmaceuticals has higher revenue and earnings than HUTCHMED. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£549.12M	3.04	-£52.98M	£2.00	96.00
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

HUTCHMED has a beta of 0.428, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Dechra Pharmaceuticals beats HUTCHMED on 6 of the 11 factors compared between the two stocks.

How does HUTCHMED compare to Hikma Pharmaceuticals?

HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£549.12M	3.04	-£52.98M	£2.00	96.00
Hikma Pharmaceuticals	£3.42B	0.93	£353.21M	£176.00	8.70

20.7% of HUTCHMED shares are held by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are held by institutional investors. 2.8% of HUTCHMED shares are held by company insiders. Comparatively, 22.3% of Hikma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Hikma Pharmaceuticals has a consensus price target of GBX 2,085.83, suggesting a potential upside of 36.24%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 3 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.05 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hikma Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

HUTCHMED has a net margin of 163.84% compared to Hikma Pharmaceuticals' net margin of 11.31%. HUTCHMED's return on equity of 36.88% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	163.84%	36.88%	-5.90%
Hikma Pharmaceuticals	11.31%	15.05%	9.40%

HUTCHMED has a beta of 0.428, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.662, suggesting that its share price is 34% less volatile than the broader market.

Summary

Hikma Pharmaceuticals beats HUTCHMED on 12 of the 16 factors compared between the two stocks.

How does HUTCHMED compare to Indivior?

Indivior (LON:INDV) and HUTCHMED (LON:HCM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, HUTCHMED had 3 more articles in the media than Indivior. MarketBeat recorded 3 mentions for HUTCHMED and 0 mentions for Indivior. Indivior's average media sentiment score of 0.64 beat HUTCHMED's score of 0.00 indicating that Indivior is being referred to more favorably in the media.

Company	Overall Sentiment
Indivior	Positive
HUTCHMED	Neutral

HUTCHMED has a net margin of 163.84% compared to Indivior's net margin of 11.44%. HUTCHMED's return on equity of 36.88% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	11.44%	-23.90%	2.37%
HUTCHMED	163.84%	36.88%	-5.90%

Indivior has higher revenue and earnings than HUTCHMED. Indivior is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A
HUTCHMED	£549.12M	3.04	-£52.98M	£2.00	96.00

Indivior has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.428, suggesting that its stock price is 57% less volatile than the broader market.

86.0% of Indivior shares are owned by institutional investors. Comparatively, 20.7% of HUTCHMED shares are owned by institutional investors. 3.4% of Indivior shares are owned by company insiders. Comparatively, 2.8% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

HUTCHMED beats Indivior on 7 of the 13 factors compared between the two stocks.

How does HUTCHMED compare to Vectura Group?

HUTCHMED (LON:HCM) and Vectura Group (LON:VEC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

20.7% of HUTCHMED shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, HUTCHMED had 3 more articles in the media than Vectura Group. MarketBeat recorded 3 mentions for HUTCHMED and 0 mentions for Vectura Group. HUTCHMED's average media sentiment score of 0.00 equaled Vectura Group'saverage media sentiment score.

Company	Overall Sentiment
HUTCHMED	Neutral
Vectura Group	Neutral

Vectura Group has lower revenue, but higher earnings than HUTCHMED. Vectura Group is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£549.12M	3.04	-£52.98M	£2.00	96.00
Vectura Group	£190.60M	0.00	N/A	£20.10	N/A

HUTCHMED has a net margin of 163.84% compared to Vectura Group's net margin of 0.00%. HUTCHMED's return on equity of 36.88% beat Vectura Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	163.84%	36.88%	-5.90%
Vectura Group	N/A	N/A	N/A

Summary

HUTCHMED beats Vectura Group on 7 of the 9 factors compared between the two stocks.

How does HUTCHMED compare to Ergomed?

HUTCHMED (LON:HCM) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

20.7% of HUTCHMED shares are held by institutional investors. Comparatively, 71.1% of Ergomed shares are held by institutional investors. 2.8% of HUTCHMED shares are held by insiders. Comparatively, 18.2% of Ergomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ergomed has lower revenue, but higher earnings than HUTCHMED. Ergomed is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£549.12M	3.04	-£52.98M	£2.00	96.00
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

HUTCHMED has a beta of 0.428, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

In the previous week, HUTCHMED had 3 more articles in the media than Ergomed. MarketBeat recorded 3 mentions for HUTCHMED and 0 mentions for Ergomed. HUTCHMED's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company	Overall Sentiment
HUTCHMED	Neutral
Ergomed	Neutral

HUTCHMED has a net margin of 163.84% compared to Ergomed's net margin of 9.87%. HUTCHMED's return on equity of 36.88% beat Ergomed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	163.84%	36.88%	-5.90%
Ergomed	9.87%	18.08%	10.16%

Summary

Ergomed beats HUTCHMED on 6 of the 11 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCM vs. The Competition

Export

Metric	HUTCHMED	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£1.67B	£12.46B	£7.16B	£2.87B
Dividend Yield	4.63%	2.62%	2.56%	6.23%
P/E Ratio	96.00	799.74	274.10	366.83
Price / Sales	3.04	763.35	656.00	83,599.70
Price / Cash	2.49	89.25	77.04	27.89
Price / Book	2.20	10.39	10.33	6.33
Net Income	-£52.98M	£2.85B	£3.50B	£5.89B
7 Day Performance	-9.43%	-3.70%	-3.35%	-0.69%
1 Month Performance	6.08%	0.78%	-0.43%	0.18%
1 Year Performance	-26.15%	3.48%	19.21%	20.03%

HUTCHMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCM HUTCHMED	N/A	GBX 192 -4.0%	N/A	-19.7%	£1.67B	£549.12M	96.00	1,760	News Coverage Gap Up
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HIK Hikma Pharmaceuticals	4.6769 of 5 stars	GBX 1,593.24 -0.7%	GBX 2,085.83 +30.9%	-7.8%	£3.33B	£3.42B	8.80	9,100	News Coverage
INDV Indivior	N/A	GBX 1,238 +1.6%	N/A	+0.0%	£1.93B	£1.40B	N/A	1,000	Gap Up High Trading Volume
VEC Vectura Group	N/A	N/A	N/A	N/A	£1.01B	£190.60M	8.20	9,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HCM) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HUTCHMED (HCM) Competitors

HCM vs. DPH, HIK, INDV, VEC, and ERGO

How does HUTCHMED compare to Dechra Pharmaceuticals?

Summary

How does HUTCHMED compare to Hikma Pharmaceuticals?

Summary

How does HUTCHMED compare to Indivior?

Summary

How does HUTCHMED compare to Vectura Group?

Summary

How does HUTCHMED compare to Ergomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HUTCHMED (HCM) Competitors

HCM vs. DPH, HIK, INDV, VEC, and ERGO

How does HUTCHMED compare to Dechra Pharmaceuticals?

Do institutionals and insiders hold more shares of HCM or DPH?

Does the media prefer HCM or DPH?

Is HCM or DPH more profitable?

Which has stronger earnings and valuation, HCM or DPH?

Which has more volatility & risk, HCM or DPH?

Summary

How does HUTCHMED compare to Hikma Pharmaceuticals?

Which has better valuation & earnings, HCM or HIK?

Do institutionals & insiders hold more shares of HCM or HIK?

Do analysts rate HCM or HIK?

Does the media prefer HCM or HIK?

Is HCM or HIK more profitable?

Which has more volatility and risk, HCM or HIK?

Summary

How does HUTCHMED compare to Indivior?

Does the media prefer INDV or HCM?

Is INDV or HCM more profitable?

Which has better valuation and earnings, INDV or HCM?

Which has more risk & volatility, INDV or HCM?

Do insiders and institutionals hold more shares of INDV or HCM?

Summary

How does HUTCHMED compare to Vectura Group?

Do insiders & institutionals believe in HCM or VEC?

Does the media prefer HCM or VEC?

Which has stronger valuation and earnings, HCM or VEC?

Is HCM or VEC more profitable?

Summary

How does HUTCHMED compare to Ergomed?

Do institutionals & insiders hold more shares of HCM or ERGO?

Which has higher valuation and earnings, HCM or ERGO?

Which has more volatility and risk, HCM or ERGO?

Does the media prefer HCM or ERGO?

Is HCM or ERGO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools